H

Herantis Pharma Oyj
OMXH:HRTIS

Watchlist Manager
Herantis Pharma Oyj
OMXH:HRTIS
Watchlist
Price: 1.32 EUR 7.32% Market Closed
Market Cap: 26.6m EUR
Have any thoughts about
Herantis Pharma Oyj?
Write Note

Intrinsic Value

HRTIS's intrinsic value estimate is unreliable because it is based only on its DCF value and doesn't use a relative valuation using multiples.

The intrinsic value of one HRTIS stock under the Base Case scenario is 0.17 EUR. Compared to the current market price of 1.32 EUR, Herantis Pharma Oyj is Overvalued by 87%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

HRTIS Intrinsic Value
0.17 EUR
Overvaluation 87%
Intrinsic Value
Price
H
Worst Case
Base Case
Best Case

Valuation Backtest
Herantis Pharma Oyj

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for HRTIS cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about HRTIS?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Herantis Pharma Oyj

Provide an overview of the primary business activities
of Herantis Pharma Oyj.

What unique competitive advantages
does Herantis Pharma Oyj hold over its rivals?

What risks and challenges
does Herantis Pharma Oyj face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Herantis Pharma Oyj.

Provide P/S
for Herantis Pharma Oyj.

Provide P/E
for Herantis Pharma Oyj.

Provide P/OCF
for Herantis Pharma Oyj.

Provide P/FCFE
for Herantis Pharma Oyj.

Provide P/B
for Herantis Pharma Oyj.

Provide EV/S
for Herantis Pharma Oyj.

Provide EV/GP
for Herantis Pharma Oyj.

Provide EV/EBITDA
for Herantis Pharma Oyj.

Provide EV/EBIT
for Herantis Pharma Oyj.

Provide EV/OCF
for Herantis Pharma Oyj.

Provide EV/FCFF
for Herantis Pharma Oyj.

Provide EV/IC
for Herantis Pharma Oyj.

Show me price targets
for Herantis Pharma Oyj made by professional analysts.

What are the Revenue projections
for Herantis Pharma Oyj?

How accurate were the past Revenue estimates
for Herantis Pharma Oyj?

What are the Net Income projections
for Herantis Pharma Oyj?

How accurate were the past Net Income estimates
for Herantis Pharma Oyj?

What are the EPS projections
for Herantis Pharma Oyj?

How accurate were the past EPS estimates
for Herantis Pharma Oyj?

What are the EBIT projections
for Herantis Pharma Oyj?

How accurate were the past EBIT estimates
for Herantis Pharma Oyj?

Compare the revenue forecasts
for Herantis Pharma Oyj with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Herantis Pharma Oyj and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Herantis Pharma Oyj against its competitors.

Analyze the profit margins
(gross, operating, and net) of Herantis Pharma Oyj compared to its peers.

Compare the P/E ratios
of Herantis Pharma Oyj against its peers.

Discuss the investment returns and shareholder value creation
comparing Herantis Pharma Oyj with its peers.

Analyze the financial leverage
of Herantis Pharma Oyj compared to its main competitors.

Show all profitability ratios
for Herantis Pharma Oyj.

Provide ROE
for Herantis Pharma Oyj.

Provide ROA
for Herantis Pharma Oyj.

Provide ROIC
for Herantis Pharma Oyj.

Provide ROCE
for Herantis Pharma Oyj.

Provide Gross Margin
for Herantis Pharma Oyj.

Provide Operating Margin
for Herantis Pharma Oyj.

Provide Net Margin
for Herantis Pharma Oyj.

Provide FCF Margin
for Herantis Pharma Oyj.

Show all solvency ratios
for Herantis Pharma Oyj.

Provide D/E Ratio
for Herantis Pharma Oyj.

Provide D/A Ratio
for Herantis Pharma Oyj.

Provide Interest Coverage Ratio
for Herantis Pharma Oyj.

Provide Altman Z-Score Ratio
for Herantis Pharma Oyj.

Provide Quick Ratio
for Herantis Pharma Oyj.

Provide Current Ratio
for Herantis Pharma Oyj.

Provide Cash Ratio
for Herantis Pharma Oyj.

What is the historical Revenue growth
over the last 5 years for Herantis Pharma Oyj?

What is the historical Net Income growth
over the last 5 years for Herantis Pharma Oyj?

What is the current Free Cash Flow
of Herantis Pharma Oyj?

Discuss the annual earnings per share (EPS)
trend over the past five years for Herantis Pharma Oyj.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Herantis Pharma Oyj

Current Assets 3.6m
Cash & Short-Term Investments 3.5m
Receivables 117k
Other Current Assets 42k
Current Liabilities 1.6m
Accounts Payable 784k
Accrued Liabilities 753k
Other Current Liabilities 46k
Non-Current Liabilities 25k
Long-Term Debt 25k
Efficiency

Earnings Waterfall
Herantis Pharma Oyj

Revenue
0 EUR
Operating Expenses
-193.6k EUR
Operating Income
-193.6k EUR
Other Expenses
-418.5k EUR
Net Income
-612.2k EUR

Free Cash Flow Analysis
Herantis Pharma Oyj

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

HRTIS Profitability Score
Profitability Due Diligence

Herantis Pharma Oyj's profitability score is 47/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROIC
ROIC is Increasing
Exceptional ROIC
Negative Free Cash Flow
47/100
Profitability
Score

Herantis Pharma Oyj's profitability score is 47/100. The higher the profitability score, the more profitable the company is.

HRTIS Solvency Score
Solvency Due Diligence

Herantis Pharma Oyj's solvency score is 67/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Negative Net Debt
Low D/E
Short-Term Solvency
67/100
Solvency
Score

Herantis Pharma Oyj's solvency score is 67/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

HRTIS Price Targets Summary
Herantis Pharma Oyj

Wall Street analysts forecast HRTIS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for HRTIS is 1.48 EUR with a low forecast of 0.71 EUR and a high forecast of 2.31 EUR.

Lowest
Price Target
0.71 EUR
46% Downside
Average
Price Target
1.48 EUR
12% Upside
Highest
Price Target
2.31 EUR
75% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for HRTIS?

Click here to dive deeper.

Dividends

Herantis Pharma Oyj
does not pay dividends
Shareholder Yield

Current shareholder yield for HRTIS is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Herantis Pharma Oyj

Country

Finland

Industry

Pharmaceuticals

Market Cap

26.6m EUR

Dividend Yield

0%

Description

Herantis Pharma Oyj engages in the research and development of biopharmaceutical products. The company is headquartered in Espoo, Etela-Suomen. The company went IPO on 2014-06-11. Leveraging research about protein dysregulation for neurodegenerative diseases, and growth stimulation in lymphatic diseases, Herantis develops a pipeline of regenerative biological and gene therapies for high impact diseases. These include CDNF biological therapy that acts on the proteostatic mechanisms of disease for the treatment of Parkinson’s disease and other neurodegenerative diseases, Lymfactin VEGF-C gene therapy for restoring lymphatic structure and function for the treatment of oncology related secondary Lymphedema and other lymphatic based diseases. Herantis is pursuing disease modifying treatments that aims to slow, stop, or even reverse the course of diseases, and bring innovation to these diseases.

Contact

ETELA-SUOMEN
Espoo
Bertel Jungin Aukio 1
+35892221195.0
herantis.com

IPO

2014-06-11

Employees

-

Officers

Chief Executive Officer
Dr. Antti Vuolanto D.Sc. (Tech)
Chief Financial Officer
Ms. Tone Kvale
Chief Scientific Officer
Dr. Henri J. Huttunen Ph.D.
Head of CMC
Mr. Jani Koskinen
Chief Medical Ofcer
Ms. Outi Lahdenperä M.D., Ph.D.
Clinical Consultant
Dr. Charlotte Videbaek M.D.

See Also

Discover More
What is the Intrinsic Value of one HRTIS stock?

The intrinsic value of one HRTIS stock under the Base Case scenario is 0.17 EUR.

Is HRTIS stock undervalued or overvalued?

Compared to the current market price of 1.32 EUR, Herantis Pharma Oyj is Overvalued by 87%.

Back to Top